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Abstract
Background: Oxidative stress and redox-regulating enzymes may have roles both in lymphomagenesis and
resistance to lymphoma therapy. Previous studies from the pre-rituximab era suggest that antioxidant enzyme
expression is related to prognosis in diffuse large B-cell lymphoma (DLBCL), although these results cannot be
extrapolated to patient populations undergoing modern treatment modalities. In this study we assessed expression
of the oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and nitrotyrosine and the antioxidant enzymes
thioredoxin (Trx), manganese superoxide dismutase (MnSOD) and glutamate-cysteine ligase (GCL) via
immunohistochemistry in 106 patients with DLBCL. All patients were treated with CHOP-like therapy combined
with rituximab. Immunostaining results were correlated with progression-free survival, disease-specific survival and
traditional prognostic factors of DLBCL.
Results: Strong 8-OHdG immunostaining intensity was associated with extranodal involvement (p = 0.00002), a
high International Prognostic Index (p = 0.002) and strong Trx (p = 0.011) and GCL (p = 0.0003) expression. Strong
Trx staining intensity was associated with poor progression-free survival (p = 0.046) and poor disease-specific
survival (p = 0.015). Strong GCL immunostaining intensity predicted poor progression-free survival (p = 0.049).
Patients with either strong Trx or strong nitrotyrosine expression showed significantly poorer progression-free
survival (p = 0.003) and disease-specific survival (p = 0.031) compared with the other patients.
Conclusions: The redox state-regulating enzymes GCL and Trx are promising markers in the evaluation of DLBCL
prognosis in the era of modern immunochemotherapy.
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Background
Of lymphomas, diffuse large B-cell lymphoma (DLBCL)
accounts for 30% to 40%. DLBCL comprises three differ-
ent subtypes as determined by gene expression profiling:
the germinal center (GC) type, the activated B-cell type
and a third heterogeneous type that cannot be included
in either of the two other categories [1]. In routine prac-
tice the subtypes are classified by means of by immuno-
histochemical grouping (Hans’ algorithm) into GC and
non-GC subtypes [2]. Standard treatment for DLBCL
consists of CHOP (cyclophosphamide, doxorubicin, vin-
cristine and prednisone) or CHOP-type regimens and
rituximab. Rituximab has revolutionized the treatment
of DLBCL by increasing survival in all International
Prognostic Index (IPI) classes [3]. New molecular mar-
kers predicting the outcome of DLBCL are still impor-
tant in order to optimize treatment.
Production of reactive oxygen species (ROS) is com-
mon to all aerobic cells, but excessive oxidative stress
may lead to variable pathological conditions. The most
important factor in the redox environment is the creation
and elimination of ROS. These are important cellular
mediators and their formation is strictly controlled under
physiological circumstances. They are mostly formed in
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the mitochondria as a by-product of oxygen metabolism.
The ROS generated in mitochondria plus, for example,
hydrogen peroxide and superoxide, can affect cellular sig-
naling pathways by activating signaling cascades or
redox-sensitive transcriptional factors. In many patholo-
gical conditions, e.g. atherosclerosis, diabetes and cancer,
ROS creation and elimination is out of control, leading to
excessive amounts [4-8]. Antioxidants are important in
the elimination of ROS, thus maintaining the normal
physiological state [9].
Redox proteins can be used in the evaluation of oxida-
tive stress. Manganese superoxide dismutase (MnSOD) is
a mitochondrial enzyme and it is the most important
superoxide dismutase in physiological conditions. Nor-
mally, MnSOD makes ROS less harmful by reducing
superoxide anions to hydrogen peroxide, which is then
neutralized to water and oxygen [10]. Thioredoxin (Trx)
functions by reducing oxidized proteins by way of
cysteine thiol-disulfide exchange and therefore it limits
the damage caused by oxidative stress [11]. Gamma
cysteine ligase (GCL) is a rate-limiting enzyme in the
creation of glutathione (GSH). Glutathione reduces disul-
fide bonds and thus repairs oxidative damage by serving
as an electron donor [12]. 8-Hydroxydeoxyguanosine (8-
OHdG) and nitrotyrosine are markers of oxidative
damage. 8-OHdG is an end-product of oxidative damage
to DNA [13]. Nitrotyrosine in its free form and in pro-
teins marks oxidative damage to protein structures [14].
Nitrotyrosine can also by itself cause DNA damage [15]
and bring about apoptosis [16].
An oxidatively balanced redox status may affect carcino-
genesis by modulating DNA in particular, but also other
cellular structures [10]. On the other hand, oxidative stress
mediates the effects of many cytostatic drugs by causing
sublethal DNA damage and thus activating apoptosis. Oxi-
dative stress markers are prognostically important, e.g. in
breast cancer [17,18], ovarian carcinoma [19], head and
neck squamous cell carcinoma [20] and acute myeloid leu-
kemia [21]. The prognostic role of oxidative stress in
DLBCL has been evaluated in two previous studies in the
pre-rituximab era, with conflicting results. The present
study was undertaken to evaluate the role of oxidative
stress and counteracting enzymes in more detail in DLBCL
patients treated with modern immunochemotherapy.
Results
Strong cytoplasmic 8-OHdG staining intensity was asso-
ciated with extranodal involvement (p = 0.00002) and a
high IPI score (divided into two groups, 0-2 and 3-5) (p =
0.002). There were no other significant associations
between clinical prognostic parameters and staining
intensities of the studied markers. The staining intensities
of Trx, GCL and nitrotyrosine correlated with the per-
centage of malignant positive cells. Intensities were
discovered to be better suited to assess survival estimates.
Staining patterns were discovered and analyzed in our
previous study [22]. The staining intensity of cytoplasmic
8-OHdG correlated with high Trx (p = 0.011) and GCL
(p = 0.0003) intensities. There were no other associations
between the studied oxidative stress markers and antioxi-
dant enzymes.
Overall 5-year progression-free survival was 81.4% and
overall 5-year DLBCL-specific survival was 87.6%. Strong
Trx staining intensity was associated with poor progres-
sion-free survival (p = 0.046) and poor disease-specific sur-
vival (p = 0.015) (Figure 1). The rate of 5-year progression-
free survival was 85.1% in patients with negative to moder-
ate Trx intensity and 57.4% in those with strong Trx
intensity. Patients with strong cytoplasmic nitrotyrosine
immunostaining had poor progression-free survival (p =
0.006; 5-year survival 85.8% in patients with negative to
moderate staining and 55.7% in those with strong positiv-
ity). Moderate to strong GCL staining intensity was asso-
ciated with worse prognosis, 5-year progression-free
survival being 87.0% versus 70.8% (p = 0.049). Likewise, 5-
year disease-specific survival was 94.6% (negative to light
GCL immunostaining) versus 77.5% (moderate to strong
GCL immunostaining) (p = 0.062). MnSOD and 8-OHdG
staining results were not associated with progression-free
or disease-specific survival.
Patients with either strong Trx or strong nitrotyrosine
immunostaining intensities had significantly poorer pro-
gression-free survival (p = 0.003) and disease-specific sur-
vival (p = 0.031) compared with the other patients. In
patients with a non-GC phenotype, strong Trx expression
was associated with progression-free survival (p = 0.010);
this was not observed in patients with a GC-phenotype.
The rate of 5-year progression-free survival was 78.4% in
patients with negative to moderate Trx immunostaining
and it was 31.6% in those with strong Trx intensity in the
non-GC phenotype group.
Discussion
This is the first study in which the prognostic value of oxi-
dative stress markers and antioxidant enzymes in DLBCL
patients treated by means of modern immunochemother-
apy has been assessed. We discovered that low immunoex-
pression of GCL, Trx and nitrotyrosine was associated
with favorable progression-free survival and Trx was also
significant as regards disease-specific survival. Intensive
Trx immunostaining also revealed a high-risk group when
only non-GC phenotype patients were included. Staining
of GCL was almost significant as regards prediction of
poor disease-specific survival. Our results suggest that
excessive antioxidant and high nitrotyrosine expression
are associated with adverse prognosis.
The prognostic role of oxidative stress in lymphomas
has been studied previously, with conflicting results. A
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study by Tome et al. (2005) [23] concerned analysis of
the levels of antioxidant enzymes and redox-associated
proteins. Their results suggested that the group with the
worst prognosis were those with decreased expression of
antioxidant enzymes, including catalase, glutathione per-
oxidase and MnSOD, and increased expression of Trx.
In a study by Andreadis et al. (2007) [24], the expres-
sion of genes in the glutathione family was examined.
Their data suggested that overexpression of these genes
correlated with worse prognosis. They used the redox
signature score created by Tome et al. [23] and found
that their results were exactly the opposite, i.e. overex-
pression of antioxidants and redox-state proteins corre-
lated with poor prognosis. However, in neither of these
studies had the patients received modern immunochem-
otherapy. Because prognostic markers are highly asso-
ciated with the therapeutic modality used, the results
cannot be extrapolated to patient populations under-
going modern treatments. We have previously carried
out thorough evaluation of the expression of oxidative
stress markers in different forms of lymphoma. In a
recent study [22] we found that high levels of GCL and
nitrotyrosine, and also low levels of MnSOD correlated
with poor prognosis, but the number of patients with
DLBCL in that study was only 18. The aim of the pre-
sent study was to assess the relationships between anti-
oxidant enzymes, oxidative stress markers and prognosis
in cases of diffuse large B-cell lymphoma treated in the
rituximab era.
At first glance the results reported by Andreadis et al.
and Tome et al. seem to be contradictory, but when eval-
uating the data according to the expression of individual
enzymes, the differences are not so striking. Comparing
the results reported by Tome et al. and those in the cur-
rent study, most are contradictory, as their data indicated
that antioxidant function would be a cellular protector.
Both our study and theirs showed that strong intensity of
Trx was associated with worse prognosis. In the study by
Andreadis et al. the authors came to the same conclusion
as ourselves, i.e. that the GSH system is related to poor
prognosis and excessive antioxidant expression worsens
the prognosis. Because the biological functions are com-
plex and antioxidant enzymes may have both positive
and negative effects on malignant cell growth, the expres-
sion of these markers should probably be analyzed indivi-
dually and also possibly disease-specifically. Redox state-
regulating enzymes may have prognostic value regardless
of treatment, since our results are largely in line with
those in two previous studies where different treatments
were applied. The expression of 8-OHdG, the most com-
monly used marker of oxidative DNA damage, is a signif-
icant prognostic factor in various solid malignancies, but
in DLBCL it does not seem to have a prognostic role.
Nevertheless, high cytoplasmic 8-OHdG expression,
which reflects ROS-derived mitochondrial DNA adduct
formation, was associated with features of aggressive dis-
ease such as high IPI class and extranodal involvement.
Expression of 8-OHdG was associated with high Trx and
GCL expression and this suggests therefore that these
enzymes might be induced under heavy oxidative stress
in DLBCL cells.
Rituximab has revolutionized DLBCL treatment and
patient prognosis. However, some patients still succumb
to their lymphomas. IPI scoring is at the moment the
only clinically relevant prognostic scoring system. Results
regarding the prognostic value of gene expression profil-
ing-based grouping are contradictory [25,26]. Unfortu-
nately, IPI scoring can no longer identify a patient
population with a 5-year prognosis of less than 50%.
Therefore, reliable biological prognostic factors and espe-
cially factors describing basic biological phenomena
which might serve as predictors of treatment results are
needed. Our results indicate that oxidative stress markers
have correlations with prognosis in cases of DLBCL. Pre-
clinical data indicate that GSH induces resistance against
key lymphoma chemotherapeutic agents. In vitro, drugs
such as indomethacin can counteract this adverse effect
by reducing GSH levels [27]. This implies that drugs that
suppress GSH might be therapeutically beneficial in lym-
phomas with high GSH expression. This may also have
relevance to the Trx system [28]. Trx is an activator of
nuclear factor B (NF-B), which inhibits apoptosis and
increases proliferation [29]. Non-GC-type DLBCL is
characterized by constitutional activation of NF-B. It
has been suggested that high levels of NF-B may be a
sign of adverse prognosis [30,31]. Our observation of
strong Trx intensity and poor prognosis in non-GC phe-
notype patients might be explained by activation of NF-
B and its anti-apoptotic properties through Trx
overexpression.
Resistance to doxorubicin [27] and vincristine [32] has
been linked to increased amounts of intracellular GSH.
Cyclophosphamide treatment depletes GSH and increases
the amount of oxidative stress in human ovarian granulosa
cells [33]. Therefore, it is plausible that an increased
amount of GSH limits the effectiveness of
Figure 1 Progression-free survival (A) and DLBCL-specific survival (B) of all patients. Strong Trx intensity was associated with both poor
progression-free (C) and disease-specific (D) survival. Nitrotyrosine as a marker of nitrosative stress was a marker of poor prognosis (E). GCL-
positive patients had worse disease-specific survival (F) and a trend towards shorter disease-specific survival (G). Patients with strong
nitrotyrosine and/or Trx expression had significantly worse relapse-free (H) and DLBCL-specific (I) survival than other patients. Trx intensity was a
powerful prognostic indicator in the non-GC group (J), but not in patients with GC phenotype.
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cyclophosphamide and might be connected to lymphoma
chemoresistance. Our results may partly be explained by
activation of GCL, which increases the amount of GSH
and may therefore bring about resistance to chemother-
apy. Doxorubicin sensitivity has also been linked to an
excessive amount of Trx [34].
Conclusions
In conclusion, oxidative stress and cellular redox state-reg-
ulating enzymes seem to play an important role in DLBCL
also in the era of modern therapies. They are of prognostic
relevance and may participate in chemoresistance. These
results should be authenticated in a prospective study and
the role of chemoresistance should be studied in lym-
phoma cell culture models. If the results can be confirmed
in vitro they probably should be taken into account in
phase I-II clinical trials dealing with patients with antioxi-
dant enzyme-overexpressing chemoresistant DLBCL.
Methods
Patient material
Table 1 summarizes the characteristics of the patients
included in the study. There were 106 patients with
histologically confirmed DLBCL from whom paraffin-
embedded tissue sections from diagnostic lymph nodes,
extralymphatic tumor site samples or coarse needle
biopsy samples were available. Detailed patient informa-
tion was collected in each case. The lymphomas were
diagnosed and treated at Oulu University Hospital and
Kuopio University Hospital between the years 2003-
2009. Diagnoses were reviewed by an experienced hema-
topathologist. The diagnostic work-up included history
and physical examination, blood chemistry, bone mar-
row biopsy and aspiration and whole body computer
tomography. The median age of the patients was 64.6
years (21-90 yr). CHOP-like therapy combined with
rituximab antibody treatment was given to all patients.
Involved field radiotherapy was applied after immuno-
chemotherapy at the sites of bulk disease with residual
masses according to individual discretion. DLBCL phe-
notypes were divided into three groups according to
Hans’ algorithm: (i) a GCB phenotype with positive CD-
10 and/or bcl-6 and negative MUM-1 immunostaining;
(ii) a non-GCB phenotype with positive MUM-1 and
positive or negative bcl-6 and negative CD-10 immunos-
taining; (iii) a third type consisting of cases with charac-
teristics of both previous types [2]. The ethical
committee of the Northern Ostrobothnia Hospital Dis-
trict has approved the study design (reference number
42/2010).
Immunohistochemical staining and sample evaluation
We used immunohistochemistry to study the expression
of 8-OHdG, nitrotyrosine, Trx, MnSOD and GCL, using
identical methods as in our recent work with different
lymphoma entities. We have previously characterized the
expression of the used antibodies in several malignant and
pre-malignant tissues [18,19,22,35,36]. Sample evaluation
in lymphomas has also been described earlier [22]. The
cytoplasmic expression was diffuse in 8-OHdG, nitrotyro-
sine, Trx and GCL. MnSOD expression was granulated, in
line with its previously described mitochondrial location.
The nuclear staining was throughout negative in nitrotyro-
sine, MnSOD and GCL. 8-OHdG and Trx showed positive
and diffuse staining in some of the malignant cells. The
nuclear membrane was pronounced in some of the sam-
ples stained with 8-OHdG. 8-OHdG and nitrotyrosine
expression in malignant cells was uniform. Trx, MnSOD
and GCL showed variable intensity in malignant cell stain-
ing in few cases. These samples were coded by using the
more dominant intensity. The staining results were evalu-
ated only in malignant lymphoma cells, since in our pre-
vious work stromal staining extent or intensity did not
show any clinical significance. The staining intensity of 8-
OHdG, nitrotyrosine, Trx and MnSOD was divided into
two groups: negative to moderate, and strong. The stain-
ing intensity of cytoplasmic GCL was divided into two
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groups: negative to light, and moderate to strong. We also
created a combination group from Trx and nitrotyrosine
immunostaining results: (i) either nitrotyrosine or Trx
immunostaining intensity strong; (ii) all other immunos-
taining results.
Statistical analyses
Progression-free survival was calculated from the date of
diagnosis to the date of relapse or date of disease-associated
death. Disease-specific survival was calculated from the
date of diagnosis to the date of death caused by lymphoma.
To assess the relationship between clinical parameters and
oxidative stress marker expression levels we used Pearson’s
chi-square test. Survival estimates were calculated by using
Kaplan-Meier analyses and statistical significance was
determined by the log-rank test. Values of p under 0.05
were considered statistically significant. All statistical ana-
lyses were performed using the Statistical Package for the
Social Sciences, v. 18.0 (Chicago, IL, USA).
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